Influenza Diagnostics Market

Influenza Diagnostics Market Outlook (2022-2032)

The global influenza diagnostics market was valued at around US$ 2.62 Billion in 2021. Sales of influenza diagnostics tests are projected to accelerate at a CAGR of 5% which will reach US$ 4.5 Billion by 2032. A combination of poor socioeconomic conditions and poor hygiene is responsible for the highest prevalence of influenza in developing nations. Hospitals and diagnostic labs are always on the lookout for products that can help treat influenza. A and B strains of the flu are more likely to cause severe health problems, so testing will be more popular in the coming years.

Technological advancements and the widespread use of smartphones are expected to increase the demand for influenza diagnostics. As smart apps are developed to detect flu in different regions, influenza diagnostics demand is expected to grow.

COVID-19 can now be diagnosed within 25 minutes through a saliva-based smartphone app developed by researchers. As part of the SmaRT-LAMP system, a saliva sample is heated on a hotplate within a heat box. Apps such as this are available online for free, and the test kits, which are one-time purchases, can be used again and again. In the future, smartphones may make it easier and less expensive to diagnose diseases around the world, say experts.

As diagnostic kits for detecting antibodies against influenza are becoming more popular in hospitals and diagnostic centers, influenza testing kits are trending up. As a result, the global influenza diagnostic tests market will flourish due to the increasing prevalence of influenza and further escalating co-morbidities and mortality rates.

Due to regular influenza epidemics, their ease of access, and a general preference for this establishment, hospitals currently hold a major share of the influenza diagnostics market. The ease of use of point-of-care testing will also increase its growth during the forecast period.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 2.62 Billion
Expected Market Value (2022)	US$ 2.75 Billion
Projected Forecast Value (2032)	US$ 4.5 Billion
Global Growth Rate (2022-2032)	5% CAGR
Expected Market Share of the U.S. Market (2032)	6.5%
Anticipated Market Value of Europe (2022-2032)	5.5%
Major Influenza Diagnostic Market Players	Thermo Fisher Scientific Hologic Quidel Corporation F. Hoffmann-La Roche AG Abbott Laboratories Becton Dickinson and Company Danaher Corporation Meridian Bioscience bioMérieux SA Luminex Corporation Siemens Healthineers AG GenMark Diagnostics Sekisui Diagnostics LLC altona Diagnostics GmbH SA Scientific ELITech Group Coris Bioconcept SPRL Mast Group Ltd.

Revenue Analysis of Influenza Diagnostics from 2017 to 2021 Vs Market Outlook from 2022 to 2032

Based on Fact.MR's global influenza diagnostics industry research, from 2017 to 2021, the global market for influenza diagnostics will grow at a 4.8% CAGR, with North America, Asia Pacific, and Europe holding significant shares.

Infectious diseases caused by viruses are known as influenza, also called 'the flu'. For identifying and diagnosing influenza, conventional and molecular diagnostic methods are used. Modern technology allows highly accurate and efficient influenza diagnosis in the market.

In order to detect influenza genetic material, RT-PCR, or reverse transcription-polymerase chain reaction, is a technique used to detect influenza genetic material. In addition to its fast results, rapid influenza diagnostic testing (RIDT) is also easy to collect, making it an excellent method for diagnosing influenza.

There will likely be a surge in the global market in the coming years due to factors such as increased influenza prevalence, increased awareness of specific diagnostic tests for early detection, molecular influenza point-of-care tests that are exempt from CLIA requirements, and a shift away from centralized laboratories towards decentralized point-of-care testing.

What are some of the major drivers of the Influenza Diagnostics Market?

Increasing awareness of early influenza diagnosis to propel Market Growth

Detecting influenza early results in better treatment. It also aids patients as well as health professionals in making important decisions about their care. In order to properly diagnose an illness in the early stages, it is important to identify the cognitive symptoms of that illness to help treat it.

Increased awareness of early disease detection among the global population is a major factor contributing to the growth of the influenza diagnostic market globally. In order to prevent and eradicate mortality from the disease, organizations are promoting early diagnosis practices.

Infectious diseases associated with bacterial, viral, and protozoal infections are diagnosed with laboratory examination, which is a very effective and popular method of testing. An extensive range of infectious diseases can be detected using immunoassays, biochemical characterization, PCR, isothermal nucleic acid amplification tests, and next-generation sequencing.

For instance, the World Health Organization developed the Global Influenza Strategy 2019-2030 to reduce the seasonal influenza burden, minimize the risk of zoonotic diseases, and minimize pandemic influenza impact. The use of diagnostic products around the world is therefore accelerating as a result of rising concerns regarding early diagnosis of influenza.

Improved Diagnostic Rapid Tests for Influenza Infection will stimulate Sales

Recent developments have made influenza diagnostic tests more useful, allowing for greater use of these tests in the healthcare industry. A variety of tests are available as part of influenza diagnostics, such as virus culture tests, RT-PCR, serology tests, rapid antigen tests, and so on.

With rapid advances in diagnostic technology, influenza diagnostic tests were previously used only in large medical facilities and diagnostic centers, but their availability in smaller clinics and research centers has made them a potentially transformative diagnostic tool for influenza.

Additionally, it is anticipated that the growth of the influenza diagnostics market will be driven by continued investments in research and innovation by established rapid diagnostic influenza testing companies so as to achieve increased test effectiveness and fewer false negatives during the forecast period.

How is the Influenza Diagnostic Market Challenged?

Stringent Regulatory Approvals are expected to curb growth of Influenza Diagnostics

The results of the influenza diagnostic test are highly influenced by the accuracy and precision of the test. Tests like these are complicated because of the antigenic variation in influenza viruses.

As a result, there are significant variations in the accuracy and specificity of influenza diagnostic tests which can affect the final results. False positives are more common during peak influenza season than false negatives. Further stringent regulations on the regular approvals of these tests in the market are expected to hamper the market growth.

Nevertheless, it is crucial that the new FDA requirements for rapid antigen flu tests are met. Therefore, since the FDA regulations are so stringent, they act as significant inhibitors to the market's growth.

Comparative View of Adjacent Influenza Diagnostics Markets

Influenza Diagnostics Market :

Attributes	Influenza Diagnostics Market
CAGR (2022-2032)	5%
Market Value (2032)	US$ 4.5 Billion
Growth Factor	As influenza prevalence rises and awareness about early detection of influenza grows, the demand for influenza diagnostic tests is expected to grow.
Opportunity	Due to increasing awareness and government initiatives for disease diagnostics, emerging markets are expected to offer lucrative growth opportunities for the influenza diagnostic market.

Reverse Transcription Polymerase Chain Reaction (RT-PCR) Market :

Attributes	Reverse Transcription Polymerase Chain Reaction (RT-PCR) Market
CAGR (2022-2032)	18%
Market Value (2032)	US$ 6.9 Billion
Growth Factor	Due to the high incidence of COVID-19 worldwide as well as the risk of infection among the geriatric population, the market is expected to grow.
Opportunity	RT-PCR assay kits are becoming increasingly popular, and technological advances in the development of these kits will enhance market opportunities.

Molecular Influenza Diagnostic Test Market :

Attributes	Molecular Influenza Diagnostic Test Market
CAGR (2022-2032)	6.9%
Market Value (2032)	US$ 1.28 Billion
Growth Factor	Due to technological advancements and increasing awareness of early disease diagnosis, the market for POC diagnostics is expected to grow significantly.
Opportunity	Patients' awareness of faster diagnostics and self-testing diagnostics are expected to create business opportunities in the coming years.

Which Regional Market is the most profitable for Influenza Diagnostics Suppliers?

China is expected to play a significant role in the growth of the influenza diagnostics market in the Asia-Pacific region. The Asia-Pacific region represents the largest market for influenza diagnostics. Increasing H1N1 and tomato flu activity in nations such as China and India, as well as suppliers' emphasis on expanding manufacturing capability, will drive demand for influenza diagnostics up significantly in the years to come.

Since North America has a large geriatric population, the market for influenza diagnostics is projected to grow significantly during the projected timeframe. Due to government initiatives, technological advancements, health awareness, and research, North America held a substantial share of the market.

Due to an increasing number of pharmaceutical companies exporting products to other regions, the European influenza diagnostics market will experience significant growth over the next few years. Also contributing to the market growth in the upcoming years there is a steep rise in consciousness among consumers, the strong support of advisory entities, and governmental support for FDA-approved tests in the market.

Country-wise Analysis

Why is influenza diagnostics experiencing major growth in the Indian market?

As influenza incidence increases, the aging population increases, and key vendors in the diagnostics market place greater emphasis on this region during the forecast period, the Indian market will grow at a CAGR of 6% during the forecast period. Patients in the region, improved collaborations with the government, and improved healthcare infrastructure are key growth determinants in this region.

Increased government support for the healthcare sector, improvement in accessibility and infrastructure, and rising healthcare demand are factors leading to favorable reimbursement conditions for diagnostic procedures. As a result of the health burden associated with the disease, the rapid growth of the population, and the increased campaign to reduce its rate, the country is experiencing rapid growth.

The growing number of governmental programs and the rising patient pool associated with COVID-19 and other rising flu-like tomato flu in recent times are expected to contribute further to the demand for influenza diagnostics in the Indian market.

What makes the U.S. a growth center for flu diagnostic product manufacturers?

Growing Geriatric Population is expected to drive demand for influenza diagnostics

The U.S. market size was valued at US$ 741 Million in 2022 and is projected to grow at a CAGR of 6.5% during the forecast period. Growing geriatric populations are expected to be one of the main drivers of market growth. A large number of diseases can affect the elderly population, including influenza.

Since the elderly are susceptible to illness due to their weakened immunity, they are at an increased risk of contracting the disease. It is apparent that geriatric populations are increasingly suffering from this disease, leading to the need for diagnostic tools to be developed.

Over-the-counter (OTC) tests that are easy to use and facilitate timely diagnosis have become more readily available due to government initiatives that enable easy diagnosis. Approximately 39% of the total influenza diagnostics market share is accounted for by the Americas. Due to the high availability and easy accessibility of modern healthcare facilities, the influenza diagnostics industry in the region is thriving.

A study by MedAlertHelp predicts that approximately 5% to 20% of Americans will develop influenza in 2022. As disease burdens continue to increase, it is expected to create a positive impact over the coming years on market growth. The proliferation of rapid diagnostic tests (RDTs) in the United States has also contributed to the increase in the adoption of these tests in the country.

Country-wise Forecast CAGRs for the Influenza Diagnostics Industry

Country	CAGR
China	5.6%
U.S.	6.5%
Australia	4%
France	5.2%

Category-wise Insights

Rapid influenza diagnostic tests (RIDT) segment driving the influenza diagnostics market growth?

RDIT demand is anticipated to increase as the Incidence of Respiratory Tract Infections Increases

Since RDIT is easy to use and easily accessible, it is expected to hold the largest market share in 2022. RDIT is also recommended by WHO as a highly sensitive, specific, and accurate method of influenza diagnosis, owing to its moderate complexity, sensitivity, and accuracy.

Clinical settings are increasingly providing surveillance and diagnostic testing for influenza diagnoses. At-home and hospital-based RIDTs are approved, and CLIA-cleared RIDTs are approved for use at the point of care. To monitor respiratory infections including influenza in athletes and coaches during the Commonwealth games 2022, ProtonDX announced its rapid and portal diagnostics tests. Therefore, RIDTs will likely be utilized at public events if surveillance and monitoring are enhanced.

In comparison to the RT-PCR test, FDA-cleared RIDTs must be able to detect influenza A and influenza B viruses with 80% sensitivity compared to RT-PCR testing. RIDTs that have been cleared by the FDA must provide 90% sensitivity for the detection of influenza A virus, and 80% sensitivity for the detection of influenza B viruses compared with viral culture.

Why is the RT-PCR Method Gaining Prominence in Biological Research?

Increasing Demand for Potentially Powerful Flu Tests will result in Growth for the Segment

It takes no longer than 2 minutes to produce results with the RT-PCR technique compared to cell cultures. Antiviral resistance can also be detected using this technique. Market growth is further expected to be boosted by advancements in these technologies.

With QuantStudio 3 and 5, Thermo Fisher Scientific Inc. offers an easy-to-use and simple RT-PCR that can be used by both beginners and experienced users alike. Through QuantStudio 3 and 5 RT-PCR, individuals are able to access and monitor their results remotely, as well as collaborate anywhere via the Thermo Fisher Cloud.

As a result, technological advances are expected to continue to fuel the market's growth over the course of the assessment period. It's expected that RT-PCR testing will gain market share in the flu diagnostics market due to the low sensitivity of RIDTs and their inability to give comprehensive information on flu types and subtypes. A number of laboratories around the world have adopted RT-PCR as a standard method to confirm whether or not they have been infected with the flu.

Market Competition

A highly competitive market is present for influenza diagnostic products in the current market scenario. Additionally, the technological advancements and innovations of the last few years have been creating an opportunity for market players by providing quick, precise, and low-cost diagnostic tests for diseases that have proven to be very efficient.

• A leading global medical technology company, BD (Becton, Dickinson, and Company) announced that BD MAXTM Respiratory Viral Panel (RVP), a combination molecular diagnostic test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV), has been CE certified as per IVD directive 98/79/EC. COVID-19 or the flu or RSV are detected using a nasal swab or nasopharyngeal swab sample. It helps clinicians to implement the right treatment plan quickly by eliminating the need for multiple tests or doctor visits. This method also speeds up diagnosis during flu season and increases testing capacity.
• An innovative biotechnology company dedicated to preventing, detecting, and diagnosing viral diseases, Virax Biolabs, has launched a rapid test kit for identifying the RSV-Influenza-COVID triple virus antigen in markets that accept CE marks, including Europe. With results typically available within 15 minutes, the testing kit can be used at home and at point-of-care for the accurate identification of infections such as a respiratory syncytial virus (RSV), influenza, and COVID-19. Sales representatives at the company can provide you with specialized diagnostic kits.

Key Segments Covered in Influenza Diagnostics Industry Research

• By Test :

  • Traditional Influenza Diagnostic Tests
    • Rapid Influenza Diagnostic Tests (RIDTs)
    • Direct Fluorescent Antibody (DFA) Tests
    • Viral Culture
    • Serological Assays
  • Molecular Influenza Diagnostic Tests
    • Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    • Isothermal Nucleic Acid Amplification Tests (INAAT)
    • Loop-Mediated Isothermal-based Amplification Assays
    • Transcription Mediated Isothermal-based Amplification Assays
    • Transcription Mediated Isothermal-based Amplification Assays

• By End User :

  • Hospitals & Clinical Laboratories
  • Diagnostic Reference Laboratories
  • Academic/Research Institutes

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA